Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The scientists from National Cancer Institute (NCI), US, have developed a new phenotypic screening platform which forecasts the efficacy of drugs developed to check blood vessel tumor growth.
Subscribe to our email newsletter
The new platform funded by the NCI and the National Institutes of Health, demonstrates how angiogenic inhibitors affect simultaneously entire cells and several steps of the angiogenesis process.
NCI radiation oncology branch staff scientist Enrique Zudaire said the platform allows them to predict what’s going to happen in preclinical models.
"This not only shortens the amount of time that you would need to do screenings and drug discovery but also enhances dramatically the success you’re going to have in the next phases," Zudaire added.
The phenotypic platform has been validated by screening 1,970 small molecules which are part of the National Cancer Institute Developmental Therapeutics Program Diversity Set.